Gotowe bibliografie tematyczne / Oncology

Gotowa bibliografia na temat „Oncology”

Autor: Grafiati
Data publikacji: 4 czerwca 2021
Data aktualizacji: 7 lipca 2024

Utwórz poprawne odniesienie w stylach APA, MLA, Chicago, Harvard i wielu innych

Wybierz rodzaj źródła:

Spis treści

Zobacz listy aktualnych artykułów, książek, rozpraw, streszczeń i innych źródeł naukowych na temat „Oncology”.

Przycisk „Dodaj do bibliografii” jest dostępny obok każdej pracy w bibliografii. Użyj go – a my automatycznie utworzymy odniesienie bibliograficzne do wybranej pracy w stylu cytowania, którego potrzebujesz: APA, MLA, Harvard, Chicago, Vancouver itp.

Możesz również pobrać pełny tekst publikacji naukowej w formacie „.pdf” i przeczytać adnotację do pracy online, jeśli odpowiednie parametry są dostępne w metadanych.

Artykuły w czasopismach na temat "Oncology"

1

Becker, Gary J. "Medical oncology, surgical oncology, radiation oncology…interventional oncology?" Journal of the American College of Radiology 2, nr 2 (luty 2005): 118–20. http://dx.doi.org/10.1016/j.jacr.2004.10.011.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
2

Amador, Daniela Doulavince, Isabelle Pimentel Gomes, Simone Elisabeth Duarte Coutinho, Teresa Neumann Alcoforado Costa i Neusa Collet. "Living pediatric oncology care and the quest for knowledge production". Revista de Enfermagem UFPE on line 4, nr 2 (31.03.2010): 666. http://dx.doi.org/10.5205/reuol.851-7033-1-le.0402201027.

Pełny tekst źródła
Streszczenie:
ABSTRACTObjectives: question nurses with pediatric oncology experience which connection is made between practice and the search for knowledge production in this area. Method: study of qualitative approach of exploratory type. The data collection technique was applied with semi-structured interview with six nurses that work in a hospital specialized in the treatment of cancer. The empirical material was submitted to thematic analysis. The project was approved by the Committee of Ethics in Research of the University Hospital Lauro Wanderley of the Federal University of Paraiba (Protocol 0124/2009) and complied with the requirements of resolution 196/96. Results: respondents nurses reported that have sought the knowledge to justify the practice in Pediatric Oncology, through specialization courses, research or professional interdependence. Continuing education in high complexity services is still an ongoing challenge for many realities so specialization and updating courses have been shown as important means for professional training. Conclusion: the process of construction of knowledge in the field of professional performance is crucial to provide care with wisdom, skill and dignity. Descriptors: oncologic nursing; pediatric nursing; education nursing; professional competence; nursing care; knowledge; oncology service, ospital.RESUMOObjetivo: questionar junto aos enfermeiros que trabalham com oncologia pediátrica qual relação é feita entre a prática e a busca pela produção de conhecimento nesta área. Método: estudo de abordagem qualitativa do tipo exploratória. A técnica de coleta de dados foi a entrevista semi-estruturada aplicada a seis enfermeiras que atuam num Hospital de referência no tratamento do câncer na Paraíba. O material empírico foi submetido à análise temática. O projeto foi aprovado no Comitê de Ética em Pesquisa do Hospital Universitário Lauro Wanderley, protocolo 0124/2009, respeitou os requisitos da Resolução 196/96. Resultados: os enfermeiros entrevistados relatam que têm buscado o conhecimento para fundamentar a prática na oncologia pediátrica, por meio de cursos de especialização, pesquisas ou interprofissionalização. A educação permanente nos serviços de alta complexidade ainda é um desafio constante para muitas realidades, portanto os cursos de especialização e atualização têm se mostrado como meios importantes para a formação profissional. Conclusão: o processo de construção do conhecimento no campo de atuação profissional é fundamental para um cuidar com sabedoria, dignidade e competência. Descritores: enfermagem oncológica; enfermagem pediátrica; educação em enfermagem; competência profissional; cuidados de enfermagem; conhecimento; serviço hospitalar de oncologia.RESUMENObjetivo: pregunta las enfermeras que trabajan con la oncología pediátrica que la relación existe entre la práctica y la búsqueda de la producción de conocimiento en esta área. Método: estudio cualitativo exploratorio. La técnica de recolección de datos fue una entrevista semi-estructurada a seis enfermeras que trabajan en un hospital de referencia para el tratamiento del cáncer en Paraíba. El material empírico fue sometido a análisis temático. El estudio fue aprobado por lo Comité Ética de Investigación del Hospital Universitario Lauro Wanderley, Protocolo 0124/09, respetó los requisitos de la Resolución 196/96. Resultados: las enfermeras entrevistadas señalaron que buscan el conocimiento para apoyar la práctica de la oncología a través de cursos especializados, de investigación e la interacción con otros profesionales. La educación continua en los servicios de alta complejidad es todavía un desafío para muchas realidades, entonces los cursos de especialización y actualización han demostrado ser un medio importante para la formación. Conclusión: el proceso de construcción de conocimiento en el ámbito de desempeño profesional es esencial para el cuidado basada en la evidencia, la dignidad y competencia. Descriptores: enfermería oncológica; enfermería pediátrica; educación en enfermería; competencia profesional; atención de enfermería; conocimiento; servicio de oncología en hospital.
Style APA, Harvard, Vancouver, ISO itp.
3

Fadol, PhD, FNP-BC, FAANP, FAAN, Anecita. "Cardio-Oncology Considerations in Oncologic Treatment Decisions". Journal of the Advanced Practitioner in Oncology 13, nr 3 (1.04.2022): 237–42. http://dx.doi.org/10.6004/jadpro.2022.13.3.11.

Pełny tekst źródła
Streszczenie:
At JADPRO Live Virtual 2021, presenter Anecita P. Fadol, PhD, FNP-BC, FAANP, FAAN, emphasized the critical role advanced practitioners play in the identification, monitoring, and management of the cardiac complications of cancer therapy. Dr. Fadol’s presentation discussed identification of the most common cardiotoxicities associated with cancer therapy, clinical considerations related to common oncologic treatments with potential cardiotoxicity that may impact cancer treatment decisions, and the management of common cardiovascular issues in patients with cancer.
Style APA, Harvard, Vancouver, ISO itp.
4

Baker, Jennifer, Daniel Brown i Samdeep Mouli. "Interventional Oncology Service Development". Seminars in Interventional Radiology 34, nr 02 (czerwiec 2017): 182–86. http://dx.doi.org/10.1055/s-0037-1601853.

Pełny tekst źródła
Streszczenie:
AbstractInterventional oncology is rapidly expanding its suite of oncologic therapies, providing unique proven therapeutic benefits. To grow a practice alongside other oncology specialties, knowledge of cancer fundamentals is required. Areas of interest include methods to assess disease stage, treatment toxicity, and response. Additionally, techniques to leverage opportunities and resources available at one's institution toward practice development and efficiency will be reviewed.
Style APA, Harvard, Vancouver, ISO itp.
5

Lombardi, Conner, Jacob Lang, Rochell Issa, Oluchi Ukaegbu Oke, Krishna Reddy i Obi Ekwenna. "Racial and ethnic representation trends in United States oncology training programs." Journal of Clinical Oncology 39, nr 15_suppl (20.05.2021): 6519. http://dx.doi.org/10.1200/jco.2021.39.15_suppl.6519.

Pełny tekst źródła
Streszczenie:
6519 Background: Utilizing race and ethnicity data from the Accreditation Council for Graduate Medical Education (ACGME), this study aims to assess representation trends across American Society of Clinical Oncology (ASCO) participant specialties from the past five academic years in order to characterize current needs and effectively address these needs moving forward. Methods: Self-reported ethnicity/race data from the ACGME database books were collected from academic years 2015-16 to 2019-2020 for the following oncologic training programs: hematology and medical oncology, medical oncology, gynecologic oncology, pediatric hematology and oncology, radiation oncology, complex general surgical oncology. Summary statistics and chi-square analysis were conducted to compare underrepresented minority (URM) trends across programs. URM groups were cross-referenced with definitions provided by the AAMC and included those who identify as Hispanic, Latino or of Spanish origin, Black or African American, and Native American or Alaskan. Results: Over the study period, only 1,250 (9.0%) of 13,853 oncology trainees identified as URM. Chi-square analysis demonstrated no significant change in URM representation in all oncology specialties combined between 2015-16 and 2019-20 (8.9% [95% CI, 7.8%-10.0%] vs. 9.7% [95% CI, 8.7%-10.8%]; P=.31). Between 2015-16 and 2019-20, Hematology and oncology (+1.3%), pediatric hematology and oncology (+0.3%) all demonstrated insignificant increasing trends in representation while radiation oncology (-0.3%), complex general surgical oncology (-4.0%) had statistically insignificant decreasing trends in representation. Gynecologic oncology (+6.0%) demonstrated a significant increasing trend in representation. Conclusions: This is the first study to characterize the vast disparities in representation in oncologic training programs in the United States. There is a demonstrated lack of representation across all oncology training programs and a lack of significant improvement over the study period. A multiprong approach is needed to improve diversity and representation across the spectrum of the oncology workforce in the United States.
Style APA, Harvard, Vancouver, ISO itp.
6

Marcu, Ioana, Eric M. McLaughlin, Silpa Nekkanti, Wafa Khadraoui, Julia Chalif, Jessica Fulton, David O’Malley i Laura M. Chambers. "Assessment of socioeconomic and racial differences in patients undergoing concurrent gynecologic oncology and urogynecology surgeries: a National Inpatient Sample (NIS) database study". International Journal of Gynecologic Cancer 34, nr 5 (maj 2024): 751–59. http://dx.doi.org/10.1136/ijgc-2023-005130.

Pełny tekst źródła
Streszczenie:
ObjectiveTo assess social determinants of health impacting patients undergoing gynecologic oncology versus combined gynecologic oncology and urogynecology surgeries.MethodsWe identified patients who underwent gynecologic oncology surgeries from 2016 to 2019 in the National Inpatient Sample using the International Classification of Diseases-10 codes. Demographics, including race and insurance status, were compared for patients who underwent gynecologic oncology procedures only (Oncologic) and those who underwent concurrent incontinence or pelvic organ prolapse procedures (Urogynecologic-Oncologic). A logistic regression model assessed variables of interest after adjustment for other relevant variables.ResultsFrom 2016 to 2019 the National Inpatient Sample database contained 389 (1.14%) Urogynecologic-Oncologic cases and 33 796 (98.9%) Oncologic cases. Urogynecologic-Oncologic patients were less likely to be white (62.1% vs 68.8%, p=0.02) and were older (median 67 vs 62 years, p<0.001) than Oncologic patients. The Urogynecologic-Oncologic cohort was less likely to have private insurance as their primary insurance (31.9% vs 38.9%, p=0.01) and was more likely to have Medicare (52.2% vs 42.8%, p=0.01). After multivariable analysis, black (adjusted odds ratio (aOR) 1.41, 95% CI 1.05 to 1.89, p=0.02) and Hispanic patients (aOR 1.53, 95% CI 1.11 to 2.10, p=0.02) remained more likely to undergo Urogynecologic-Oncologic surgeries but the primary expected payer no longer differed significantly between the two groups (p=0.95). Age at admission, patient residence, and teaching location remained significantly different between the groups.ConclusionsIn this analysis of a large inpatient database we identified notable racial and geographical differences between the cohorts of patients who underwent Urogynecologic-Oncologic and Oncologic procedures.
Style APA, Harvard, Vancouver, ISO itp.
7

Gray, Natalie N., Lindsay R. Villalobos, Milre Matherne, Aric Schadler i Tyler E. Bosley. "Association of Chemotherapy Regimen Intensity and Use of Psychotropic Medications in Pediatric Oncology Patients". Journal of Pediatric Pharmacology and Therapeutics 27, nr 7 (1.09.2022): 649–54. http://dx.doi.org/10.5863/1551-6776-27.7.649.

Pełny tekst źródła
Streszczenie:
OBJECTIVE Pediatric oncology patients endure treatments that may include chemotherapy, surgery, radiation, and transplant. These treatment modalities often have an effect on a patient's mental health. To date, little is known or published about the association between certain cancer treatment regimens and the use of psychotropic medications. The goal of this study is to identify associations between the use of psychotropic medications in pediatric oncology patients in relation to the intensity of their oncologic treatment regimen. METHODS A retrospective chart review was completed for pediatric oncology patients seen between the years of 2009 and 2019 with prescriptions and/or inpatient orders for specific psychotropic medications. The intensity of the oncologic regimen was categorized using the Intensity of Treatment Rating Scale (ITR-3) tool. Association between the intensity of therapy and use of psychotropic medications were compared using Pearson χ2 and Fisher exact tests as appropriate. RESULTS There were 172 patients identified as having inpatient and/or outpatient orders for psychotropic medications during the study period. Ninety-one pediatric oncology patients were included in data analysis. It was found that psychotropic medications were used consistently in pediatric oncology patients despite a specific ITR-3 score. There were no statistically significant associations found when comparing ITR-3 scores to psychotropic medication use or to age at diagnosis. CONCLUSIONS Significance was not obtained in this study; however, we found that psychotropic medications were used across the spectrum of diagnoses, age, and oncologic treatment intensity. This suggests that all pediatric oncology patients should be evaluated for psychiatric needs throughout their course of oncologic treatment.
Style APA, Harvard, Vancouver, ISO itp.
8

Karel, Nešpor. "Alcohol abuse and oncology". Cognitive Remediation Journal 9, nr 4 (20.10.2020): 28–32. http://dx.doi.org/10.5507/crj.2020.005.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
9

Rosenblum, Rachel, Ran Huo, Bethann Scarborough, Nathan Goldstein i Cardinale B. Smith. "Comparison of Quality Oncology Practice Initiative Metrics in Solid Tumor Oncology Clinic With or Without Concomitant Supportive Oncology Consultation". Journal of Oncology Practice 14, nr 12 (grudzień 2018): e786-e793. http://dx.doi.org/10.1200/jop.18.00380.

Pełny tekst źródła
Streszczenie:
Purpose: The Quality Oncology Practice Initiative (QOPI) is a quality measurement and improvement program designed to assess practice performance for various consensus-based and evidence-based measures. In this study, we evaluated differences in QOPI metrics met among patients with advanced solid cancer receiving routine oncologic care alone (routine care) compared with patients receiving integrated oncology and specialty-level palliative care (supportive care). Methods: We conducted a retrospective chart review of 100 randomly selected patients treated between June 2013 and June 2015 from our supportive care group and matched these patients to 100 routine care group patients on the basis of tumor type and initial oncology visit date. We used the electronic medical record to collect data regarding patient demographics, palliative care–specific QOPI metrics, intensive care unit admissions, and hospice enrollment. We performed multivariate analysis comparing differences between the two groups. Results: A total of 200 patients were included. Both groups had similar baseline characteristics. Supportive care consultation improved the absolute number of QOPI metrics met ( P = .01). The QOPI metrics more likely to be met included the following: pain appropriately addressed ( P < .01), advance care directives documented by third office visit ( P < .01), and longer hospice enrollment ( P < .01). Conclusion: Integrating palliative care consultation with routine oncologic care improved pain management and end-of-life planning and care. Properly addressing pain and guiding advance care discussions require specialized skills. These data support the need for increased primary palliative care education for oncologists and further development of supportive oncology practices.
Style APA, Harvard, Vancouver, ISO itp.
10

Sória, Denise de Assis de Corrêa, Ailse Rodrigues Bittencourt, Maria de Fátima Batalha de Menezes, Célia Antunes Crisóstomo de Sousa i Sônia Regina de Souza. "Resiliência na área da Enfermagem em Oncologia". Acta Paulista de Enfermagem 22, nr 5 (październik 2009): 702–6. http://dx.doi.org/10.1590/s0103-21002009000500017.

Pełny tekst źródła
Streszczenie:
Este estudo objetivou mapear a produção científica, nacional e internacional, sobre a resiliência na Enfermagem em Oncologia e discutir sua aplicabilidade na assistência. Resiliência origina-se do latim resiliens e significa saltar para trás, voltar, ser impelido, recuar, encolher-se, romper. Trata-se de revisão sistemática sem meta análise nas bases de dados Public Medical (PubMed), Literatura Internacional em Ciências da Saúde (Medline), Literatura Latino-Americana e do Caribe em Ciências da Saúde (LILACS) e Base de Dados de Enfermagem (BDENF) e nos sites da Oncology Nursing Society e da International Society of Nurses in Cancer Care. Os descritores foram: resilience e nursing; resilience, cancer e oncology; resilience, nursing, cancer e oncology; resiliência e enfermagem; resiliência, câncer e oncologia; resiliência, enfermagem, câncer e oncologia. Foram encontrados 116 artigos e selecionados cinco artigos que abordam a resiliência vinculada à Enfermagem em Oncologia. Verifica-se uma lacuna na utilização do conceito na Enfermagem em Oncologia na América Latina, e incipiência nas produções internacionais. Há necessidade do incremento da abordagem da resiliência nessa área e ampliação da discussão na temática.
Style APA, Harvard, Vancouver, ISO itp.
Więcej źródeł

Rozprawy doktorskie na temat "Oncology"

1

Breit, Elyse. "Education for Pediatric Oncology Nurses on Fertility Preservation of Pediatric Oncology Patients". Honors in the Major Thesis, University of Central Florida, 2014. http://digital.library.ucf.edu/cdm/ref/collection/ETH/id/1578.

Pełny tekst źródła
Streszczenie:
Although the survival rate of childhood cancer is high, nearly two thirds of these survivors experience negative long-term secondary side effects from cancer treatments. Infertility is one such side effect that can have a prominent impact on quality of life as the patient ages. It is important for nurses working with pediatric oncology patients to provide the patient and family with education about risk for infertility and fertility preservation (FP) in order to allow families to make decisions about FP before cancer treatment starts. However, pediatric oncology nurses report being uneducated about FP guidelines and are hesitant to broach this subject with families. The purpose of this HIM thesis is to review nurse perceived barriers related to educating patients and their families about the risk for infertility following cancer treatments and FP and to make recommendations for improving communication between nurses and families about FP. A search was performed using CINAHL, PreCINAHL, PsychINFO, PsychARTICLES, and Medline databases and examined peer-reviewed quantitative and qualitative research studies. Key terms used in the database searches were ped' OR child', onco' OR cancer', fert', and nurs'. Findings indicated that there were many barriers for pediatric oncology nurses, which inhibited the discussion of FP with patients and families such as lack of knowledge and resources, provider attitudes toward FP, and patient factors. Based on the findings, the researcher identified several interventions to aid pediatric oncology nurses in overcoming these barriers to FP discussion.
B.S.N.
Bachelors
Nursing
Nursing
Style APA, Harvard, Vancouver, ISO itp.
2

Gananadha, Sivakumar St George UNSW. "Radiofrequency ablation in oncology". Awarded by:University of New South Wales. St George, 2006. http://handle.unsw.edu.au/1959.4/24347.

Pełny tekst źródła
Streszczenie:
Radiofrequency ablation (RFA) is an established treatment option for patients with inoperable liver tumours and is now being investigated for the treatment of lung and other solid tumours. The aim of this thesis was to investigate the use RFA to decrease blood loss during liver resection, for the treatment of the liver resection edge and to investigate the safety and efficacy of brain RFA. Blood loss is an important factor affecting both the morbidity and mortality following liver resection. The use of a novel in line RF probe to ablate the transection plane prior to liver resection resulted in decreased blood loss with easier resection. This has potential in the treatment of liver tumors in cirrhotic livers and also in other vascular organs. The other important prognostic factor affecting long-term survival in patients undergoing liver resection for liver tumors is the surgical margins. Positive margins which cannot be treated with repeat resection may be treated with cryotherapy. The use of a novel probe to ablate the resection edge with RFA was found to be equally effective as cryotherapy and superior to argon beam coagulation or diathermy in an ex-vivo model. The radiofrequency ablation of the brain was found to be safe with no hemorrhage or damage to the surrounding brain parenchyma. There was no rise in intra-cranial pressure in the animals treated with RFA. The brain RFA was found to be effective and has potential for the treatment of brain tumours. Dispersive pad site burns was a significant problem in patients treated with radiofrequency ablation for lung and liver tumours occurring in 5% of patients. Pad tissue temperature of 45oC was found to be the threshold temperature above which burns occurred. Monitoring of pad-tissue temperatures with thermocouples and application of ice packs in addition to increasing the number of pads may help decrease this complication.
Style APA, Harvard, Vancouver, ISO itp.
3

Blackwelder, Reid B. "Integrative Approaches to Oncology". Digital Commons @ East Tennessee State University, 2006. https://dc.etsu.edu/etsu-works/6986.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
4

Wiebe, Leonard Irving. "Radiopharmaceuticals for diagnostic oncology". Thesis, The University of Sydney, 2001. https://hdl.handle.net/2123/28451.

Pełny tekst źródła
Streszczenie:
Medicinal Chemistry and the Radiopharmaceutical Sciences The radiopharmaceutical sciences are founded in Medicinal Chemistry and applied in Nuclear Medicine. The radiopharmaceutical sciences include a large component of drug design and development, and encompass the physics and chemistry of radionuclide production using nuclear reactors and charged particle accelerators (c.g. cyclotrons), as well as the synthesis and radiolabelling of precursor molecules, radiation dosimetry, biological testing, pharmacokinetic and kinetic modeling, and the administration of diagnostic and therapeutic doses of radiopharmaceuticals to patients. Radiopharmacy, as it pertains more narrowly to the practice of pharmacy, is a subdiscipline of medicinal and pharmaceutical chemistry in many Schools of Pharmacy. In several countries, radiopharmacy (or nuclear pharmacy) practice is recognized as a professional sub-specialty in Pharmacy, and is governed by state regulatory authority. Radiopharmaceutical research and radiopharmacy practice are also found within academic departments in chemistry and physics, and are practiced in nuclear medicine departments of major hospitals, worldwide. My research has evolved from medicinal chemistry, with a focus on the design, synthesis, radiolabelling, and biological and clinical evaluation of novel compounds that are of medicinal interest. Personal Contributions to the Submitted Publications Radiopharmaceutical chemistry and the development of radiopharmaceuticals is the pervading theme of the research publications arising from my research activities. The publications presented in this submission are based on research conducted primarily at the Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, and the Cross Cancer Institute (Edmonton). Research collaborations have included scientists from the Deutsches Krebsforschungszentrum (Heidelberg), the Tuebingen Universitaet PET Center (Tuebingen), the Daniel den Hoed Cancer Hospital (Rotterdam), the Rega Institute (Leuven), Ansto (Sydney), the University College of London Medical School (London) and the Peter MacCallum Cancer Institute (Melbourne). Publications submitted date from 1970 through 2000. The early publications (to the late 1970's) reflect research that I have either conducted or assisted in personally at the research bench. The majority of the remaining papers reflect my research leadership in terms of concepts, experimental design and execution, and manuscript preparation. It is my practice to actively participate in all publications that I co-author, and in general, to place the names of junior scientists (e.g. graduate students) ahead of senior co-authors. In no case am I a co—author because of administrative positions I have held (e.g. Division head; Director). The senior collaborators who have influenced the scientific evolution of my work are named in the following paragraphs. Junior scientists (e.g. graduate students, post-doctoral fellows, research associates) have made important contributions, especially at the research bench. The manuscripts are grouped into three main categories, which are introduced in the following paragraphs. Published abstracts, and international patents on hypoxia imaging, gene therapy imaging, and drug delivery based on cyclodextrins, are not included in this material.
Style APA, Harvard, Vancouver, ISO itp.
5

Camacho, Castillo Luz del Carmen. "Acid ceramidase and sphingosine-1-phosphate lyase as biomarkers and therapeutic targets in cancer. (Ceramidasa ácida y Esfingosina-1-fosfato Liasa como biomarcadores y dianas terapéuticas en cáncer)". Doctoral thesis, Universitat de Barcelona, 2011. http://hdl.handle.net/10803/21624.

Pełny tekst źródła
Streszczenie:
Cer and So are involved in regulation of apoptosis and cell cycle arrest while on the other hand S1P promotes cell growth and inhibits apoptosis. The antagonistic effects of these metabolites are regulated by enzymes that interconvert Cer, So, and S1P. In this work two of these enzymes were studied: sphingosine phosphate lyase and acid ceramidase. First several methods to determine the activity of these enzymes were developed and optimized, resulting in the publication of sensitive fluorogenic and chromatographic methods for enzyme activity. Particularly the assay optimized for acid ceramidase activity was used in the finding and identification of new inhibitors in several compound libraries. As a result compounds RBM2-1B, RBM2-1D and RBM2-1E were identified as acid ceramidase and dihydroceramide desaturase inhibitors. Furthermore compounds RBM1-12, RBM1-13 and SABRAC were also described as acid ceramidase inhibitors. Since several publications described the upregulation of acid ceramidase in advanced prostate cancer, we decided to investigate the particular effect of the acid ceramidase inhibition in a cellular model of advanced prostate cancer. Using cells PC-3/Mc we inhibited acid ceramidase through two different approaches: first silencing the gen ASAH1 and comparing the effects with chemical inhibition of the enzyme using compounds RBM1-12, RBM1-13 and SABRAC. We evaluate the effect of acid ceramidase inhibition in cell growth, invasivity and 3D growth in vitro, finding a diminished growth and 3D growth in both cells those knockdown for ASAH1 and treated with inhibitors. Finally, the effect of ASAH1 silencing in in vivo tumor growth and lung colonization was also determined. To this end male NOD-SCID mice were used for xenotransplants with cells PC-3/Mc_ASAH1_KD or control and the tumor growth or lung colonization was followed by luminometry. We found that the silencing of ASAH1 in PC-3/Mc cells delayed the growth and also the lung colonization, highlighting the potential of acid ceramidase inhibition as adjuvant in the treatment of prostate cancer and also in the prevention of metastases formation.
Style APA, Harvard, Vancouver, ISO itp.
6

Aguilera, Peiró Paula. "Susceptibilidad a Melanoma: nuevos aspectos clínico-patológicos, desarrollo de herramientas y modelos de estudio y evaluación de medidas preventivas". Doctoral thesis, Universitat de Barcelona, 2015. http://hdl.handle.net/10803/565908.

Pełny tekst źródła
Streszczenie:
El trabajo contenido en esta Tesis Doctoral ha ido encaminado a mejorar el conocimiento del Melanoma Familiar con el fin de mejorar su prevención y tratamiento. En el primero de los trabajos publicados se han descrito y validado las características clínicas, histopatológicas e inmunohistoquímicas del melanoma (MM) familiar, que van a ser de utilidad para el clínico en el momento de plantear a quién ofrecer un estudio genético. Estos hallazgos van a permitir un mayor entendimiento entre la interrelación genética y ambiente en estos tumores. Con el fin de poder llevar a cabo estos estudios histopatológicos, inmunohistoquímicos, y mucho más importante hoy en día, estudios moleculares, en el segundo trabajo se explica el desarrollo y validación de un método de muestreo tumoral para la obtención de tejido para biobanco basado en la dermatoscopia ex vivo. En la era de la biología molecular y de las terapias diana dirigidas contra el cáncer, la investigación traslacional para identificar nuevas dianas terapéuticas en el MM ofrece nuevas oportunidades para potenciales nuevos tratamientos. El tener muestras de tumor primario es de grandiosa utilidad para el paciente. El protocolo diseñado de muestreo tumoral nos va a permitir la obtención de muestras para el biobanco, preservando la arquitectura del tumor. Para comprender mejor la patogenia del MM familiar son necesarios modelos de estudio que nos permitan abordar la compleja interrelación de estos pacientes con lam RUV. Debido a la complejidad de llevar a cabo estos trabajos con pacientes, en el cuarto trabajo se ha desarrollado un modelo murino humanizado de MM familiar que se ha constatado eficaz para el estudio de la interacción entre factores genéticos como mutaciones en CDKN2A o polimorfismos en MC1R y la RUV. Finalmente se ha evaluado una estrategia de fotoprotección sistémica mediante la realización del tercer trabajo, y se ha constatado eficaz en individuos portadores de genotipos de riesgo.
The work contained in this thesis has been aimed at improving the knowledge of familial Melanoma (MM) in order to improve prevention and treatment. In the first published paper, clinical, histopathologic and immunohistochemical features of familial MM have been described and validated. All this new information will be useful to the clinician at the moment of asking who to offer a genetic study. These findings will allow a greater understanding between the interrelationship of genetics and environment in these tumors. In order to carry out these histopathologic studies, immunohistochemical, and much more important today, molecular studies, in the second paper we explain the development and validation of a method of sampling tumor for obtaining tissue for the dermatoscopy-based BioBank ex vivo. In the era of molecular biology and diana directed therapies against cancer, translational research to identify new therapeutic targets in the MM offers new opportunities for potential new treatments. Having samples of primary tumor is of great utility for the patient. The designed tumor sampling protocol will allow us to obtain samples to the BioBank, preserving the architecture of the tumor. To better understand the pathogenesis of familial MM models of study that will allow us to tackle the complex interrelation of these patients with the RUV are necessary. Due to the complexity of carrying out these works with patients, in the fourth paper a model humanized murine family MM has been developed, and has been effective for the study of the interaction between genetic factors such as mutations in CDKN2A or polymorphisms in MC1R and UVR. Finally a strategy of systemic photoprotection has been evaluated in the third work, and has been found effective in individuals carrying risk genotypes.
Style APA, Harvard, Vancouver, ISO itp.
7

Lau, Phyllis Min-yu. "Adverse drug reactions in oncology". Monash University, Dept. of Pharmacy Practice, 2003. http://arrow.monash.edu.au/hdl/1959.1/5549.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
8

Hugtenburg, Richard P. "Computational methods in radiation oncology". Thesis, University of Canterbury. Physics and Astronomy, 1998. http://hdl.handle.net/10092/6796.

Pełny tekst źródła
Streszczenie:
This thesis examines computer technology in radiation oncology and the intimate role that it must now play in the dosimetry practices of this discipline. Aspects of the dosimetry and implementation of five radiation therapies are examined, namely total-body irradiation (TBI), total-skin electron therapy (TSET), electron therapy, superficial therapy and ophthalmic brachytherapy. Computational techniques, in particular, Monte Carlo and several other numerical methods are used. The Monte Carlo platform, EGS4, and the treatment planning system, GRATIS, have been implemented on SUN and Silicon Graphics workstations. Monte Carlo methods are used in the investigation of electron therapy planning and superficial and brachytherapy dosimetry practices. Monte Carlo techniques are used for radiation protection calculations of linear accelerator bunker design and for the optimisation of an in vivoX-ray fluorescence (XRF) technique used to measure platinum uptake associated with cisplatin chemotherapy. Inverse Monte Carlo methods have been examined and implemented. Inverse methods, applied to in-phantom dose measurements, are used to determine phase-space information. such as spectra, for an incident electron beam. Analogous methods are examined for megavoltage and superficial X-rays in particular, source parameterisation with attenuation and photoactivation techniques. Two linear accelerators, a Varian 2100C and a Varian 600C, provide Megavoltage X-rays or electrons. The TBI therapy uses a 6 MV X-ray beam. The TSET technique uses 6 MeV electrons which degraded to a lower energy by a screen placed in front of the patient at an extended source distance. The 9 Me V and the 20 Me V electron modalities are also closely examined. Two Philips superficial therapy units, RT100 and RT50 provide 10 through 100 kVp X-rays. 1251 seeds are used for the investigation of ophthalmic brachytherapy dosimetry. Methods of dosimetry incorporated in this work include in-phantom, ionisation chamber and diode measurements. Thermoluminescent dosimeters (TLDs), Silverhalide and radio chromic films are used. Measurements have been performed in water, solid water. polymethyl-methacrylate (PMMA), and polystyrene phantoms. Fricke, ferrous based gels are investigated as a method of dosimetry in a uniform medium. Three-dimensional dose distributions are examined for several radiation modalities. The concentration of radiation-induced ferric ions and hence dose is determined using magnetic resonance imaging (MRI). A high-purity germanium detector and a thalium doped sodium iodide detector are employed for the measurement of source spectra and for fluorescing and activated materials.
Style APA, Harvard, Vancouver, ISO itp.
9

Fröhner, Michael, Oliver W. Hakenberg i Manfred P. Wirth. "Molecular Therapy in Urologic Oncology". Saechsische Landesbibliothek- Staats- und Universitaetsbibliothek Dresden, 2014. http://nbn-resolving.de/urn:nbn:de:bsz:14-qucosa-133789.

Pełny tekst źródła
Streszczenie:
During recent years, significant advances have been made in the field of molecular therapy in urologic oncology, mainly for advanced renal cell carcinoma. In this hitherto largely treatment-refractory disease, several agents have been developed targeting the von Hippel-Lindau metabolic pathway which is involved in carcinogenesis and progression of the majority of renal cell carcinomas. Although cure may not be expected, new drugs, such as the multikinase inhibitors sorafenib and sunitinib and the mammalian target of rapamycine inhibitor temsirolimus, frequently stabilize the disease course and may improve survival. Fewer data are available supporting molecular therapies in prostate, bladder, and testicular cancers. Preliminary data suggest a potential role of high-dose calcitriol and thalidomide in hormone-refractory prostate cancer, whereas targeted therapies in bladder and testicular cancers are still more or less limited to single-case experiences. The great theoretical potential and the multitude of possible targets and drug combinations, however, support further research into this exciting field of medical treatment of urologic malignancies
Dieser Beitrag ist mit Zustimmung des Rechteinhabers aufgrund einer (DFG-geförderten) Allianz- bzw. Nationallizenz frei zugänglich
Style APA, Harvard, Vancouver, ISO itp.
10

Loyd, Roylin F. "Mentoring potential of oncology nurses". Virtual Press, 1995. http://liblink.bsu.edu/uhtbin/catkey/941369.

Pełny tekst źródła
Streszczenie:
Nurses in management and clinical positions in all areas of the country are experiencing role changes due to restructuring within the health care industry. Nurses have an opportunity to embrace and enhance these changes as the trend toward Patient Focused Care continues which entails a restructuring of care delivery at all levels.Oncology nurses are specifically encouraged by the Oncology Nursing Society to mentor other nurses. The purpose of this study was to examine the concept of mentoring as related to oncology nurses who have experienced role changes due to redesigns in the health care delivery systems. The theoretical framework used in this study was Benner's "From Novice to Expert."A convenience sample of 88 oncology nurses were surveyed. The Darling Measuring Mentoring Potential Scale (MMP), a demographic questionnaire, and a cover letter were mailed. Respondent confidentiality was maintained and the procedures for protection of human subjects were followed. A descriptive correlational design was used. The research questions were analyzed using Pearson's correlation coefficient and multiple regression analysis. Means and standard deviation of mentoring characteristics were also obtained on the clustered scores. Findings of the study indicated a small, but significant difference between levels of education, role changes and mentoring potential. Levels of education and role changes accounted for 15% of the differences in mentoring potential scores. However, the mean scores for both the clustered basic and supporting mentoring characteristics were below the suggested scores as suggested for a substantial mentoring relationship.Conclusions from the study were that the concept of mentoring is still not prevalent among oncology nurses and does not play an important role in the professional lives of the respondents. The concept of mentoring needs to be formally addressed in nursing education as well as in hospital staff education and leadership programs. There needs to be continuing research regarding the concept of mentoring within the nursing profession in order to promote the benefits of this concept so that nurses may join with those in other professions to enjoy the products of mentoring.
School of Nursing
Style APA, Harvard, Vancouver, ISO itp.
Więcej źródeł

Książki na temat "Oncology"

1

Inc, Ovid Technologies, red. Cancer: Principles and practice of oncology. Wyd. 6. Philadelphia: Lippincott, Williams & Wilkins, 2001.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
2

1912-, Shimkin Michael Boris, red. Oncology. Austin, Tex: Silvergirl, 1986.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
3

Chang, Alfred E., Daniel F. Hayes, Harvey I. Pass, Richard M. Stone, Patricia A. Ganz, Timothy J. Kinsella, Joan H. Schiller i Victor J. Strecher, red. Oncology. New York, NY: Springer New York, 2006. http://dx.doi.org/10.1007/0-387-31056-8.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
4

E, Britton Keith, Clarke Susan E. M i British Nuclear Medicine Society, red. Oncology. [London]: British Nuclear Medicine Society, 1995.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
5

Oncology. Philadelphia: W.B. Saunders, 2004.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
6

E, Graham Jennifer, red. Oncology. Philadelphia: W.B. Saunders, 2004.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
7

T, Gorman Neil, red. Oncology. New York: Churchill Livingstone, 1986.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
8

J, Spence Roy A., i Johnston Patrick G. MD, red. Oncology. Oxford: Oxford University Press, 2001.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
9

Val, Powell, POSTRAD i Wigan Foundation for Technical Education., red. Oncology. Lancaster: POSTRAD, 1985.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
10

Ann, Faulkner, red. Oncology. London: Scutari, 1990.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
Więcej źródeł

Części książek na temat "Oncology"

1

Kilbourn, Kristin M., i Patricia E. Durning. "Oncology and Psycho-Oncology". W Handbook of Clinical Health Psychology, 103–29. Chichester, UK: John Wiley & Sons, Ltd, 2005. http://dx.doi.org/10.1002/0470013389.ch7.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
2

Elgazzar, Abdelhamid H., i Ismet Sarikaya. "Oncology". W Nuclear Medicine Companion, 257–308. Cham: Springer International Publishing, 2018. http://dx.doi.org/10.1007/978-3-319-76156-5_10.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
3

Char, Devron H. "Oncology". W Risk Prevention in Ophthalmology, 181–85. New York, NY: Springer New York, 2008. http://dx.doi.org/10.1007/978-0-387-73341-8_17.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
4

Cannon, Shanklin B. "Oncology". W Brackenridge’s Medical Selection of Life Risks, 711–44. London: Palgrave Macmillan UK, 2006. http://dx.doi.org/10.1007/978-1-349-72324-9_26.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
5

Vinti, Luciana, Angela Mastronuzzi, Giuseppe Maria Milano, Evelina Miele, Raffaele Cozza i Franco Locatelli. "Oncology". W Conventional Nuclear Medicine in Pediatrics, 123–26. Cham: Springer International Publishing, 2016. http://dx.doi.org/10.1007/978-3-319-43181-9_11.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
6

Nahler, Gerhard. "oncology". W Dictionary of Pharmaceutical Medicine, 126. Vienna: Springer Vienna, 2009. http://dx.doi.org/10.1007/978-3-211-89836-9_963.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
7

Suskind, David L., i Polly Lenssen. "Oncology". W Pediatric Nutrition Handbook, 123–26. West Sussex, UK: John Wiley & Sons, Ltd., 2013. http://dx.doi.org/10.1002/9781118785034.ch10.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
8

Cannon, Shanklin B. "Oncology". W Brackenridge’s Medical Selection of Life Risks, 711–44. London: Palgrave Macmillan UK, 2006. http://dx.doi.org/10.1007/978-1-349-56632-7_26.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
9

Hui, David. "Oncology". W Approach to Internal Medicine, 185–232. Boston, MA: Springer US, 2010. http://dx.doi.org/10.1007/978-1-4419-6505-9_7.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
10

Schaarschmidt, Benedikt M., Lino M. Sawicki, Gerald Antoch i Philipp Heusch. "Oncology". W PET/MR Imaging: Current and Emerging Applications, 23–52. Cham: Springer International Publishing, 2017. http://dx.doi.org/10.1007/978-3-319-69641-6_3.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.

Streszczenia konferencji na temat "Oncology"

1

Mocna, Marta, Carlos Granja, Claude Leroy i Ivan Stekl. "Hyperthermia in Oncology". W Nuclear Physics Medthods and Accelerators in Biology and Medicine. AIP, 2007. http://dx.doi.org/10.1063/1.2825805.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
2

Volobuev, P. V., E. D. Uskov, M. V. Ulitko, K. O. Khohlov, A. P. Volobuev, A. V. Belousova i E. V. Moisejkin. "Magnetotherapy in oncology". W THE VII INTERNATIONAL YOUNG RESEARCHERS’ CONFERENCE – PHYSICS, TECHNOLOGY, INNOVATIONS (PTI-2020). AIP Publishing, 2020. http://dx.doi.org/10.1063/5.0032561.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
3

"Clinical oncology – service". W Proceedings of UK Imaging and Oncology Congress Online 2021. The British Institute of Radiology, 2021. http://dx.doi.org/10.1259/conf-pukrc.2021-k-oncoser.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
4

"Clinical oncology – therapy". W Proceedings of UK Imaging and Oncology Congress Online 2021. The British Institute of Radiology, 2021. http://dx.doi.org/10.1259/conf-pukrc.2021-c-onco.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
5

Wood, Mary McGee. "Dialogue tagsets in oncology". W the Second SIGdial Workshop. Morristown, NJ, USA: Association for Computational Linguistics, 2001. http://dx.doi.org/10.3115/1118078.1118105.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
6

Korytova, Luiza, Evgenii Buzov, Oleg Korytov i Larisa Rybina. "NONLINEAR EFFECTS IN ONCOLOGY". W XV International interdisciplinary congress "Neuroscience for Medicine and Psychology". LLC MAKS Press, 2019. http://dx.doi.org/10.29003/m443.sudak.ns2019-15/237-238.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
7

Ferrari, Mauro. "Nanotechnology and individualized oncology". W AACR International Conference: Molecular Diagnostics in Cancer Therapeutic Development– Sep 27-30, 2010; Denver, CO. American Association for Cancer Research, 2010. http://dx.doi.org/10.1158/diag-10-ed1a-1.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
8

Loewe, Robert P. "Organ-agnostic precision oncology". W RExPO22. ScienceOpen, 2022. http://dx.doi.org/10.14293/s2199-1006.1.sor-.pppedsdp.v1.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
9

Menyaev, Y. A., i V. P. Zharov. "Phototherapeutic technologies for oncology". W SPIE Proceedings, redaktorzy Andrei V. Ivanov i Mishik A. Kazaryan. SPIE, 2005. http://dx.doi.org/10.1117/12.640217.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
10

Pâslaru, Ana Maria, Ana Maria Fătu, Alexandru Nechifor, Laura Florentina Rebegea, Diana Bulgaru Iliescu i Anamaria Ciubara. "PSYCHO-ONCOLOGY. CASE PRESENTATION". W The European Conference of Psychiatry and Mental Health "Galatia". Archiv Euromedica, 2023. http://dx.doi.org/10.35630/2022/12/psy.ro.35.

Pełny tekst źródła
Streszczenie:
Increased survival of oncology patients brings to attention new aspects of adverse effects due to antineoplastic treatment. Psychiatric disorders, cardiovascular disorders as well as the progressive incidence of multiple primary neoplasia are some of the most common side effects. Aim: Care of the oncology patient undergoes an important period of change, from the management of tumor disease to the multidisciplinary approach, centered on improving the quality of life. Method: We present the case of a 75-year-old patient, whose personal pathological history reveals the presence of a diagnosis of left testicular seminoma, in 1978, for which he received radiochemical therapy. An oncological patient under long-term medical supervision for several decades is diagnosed in November 2017 with urothelial carcinoma, infiltrative, invasive in his own muscle patch, pT2NxMx. Approximately 40 years later, the second neoplastic site, the malignant bladder tumor, appears. Facing this diagnosis, the patient becomes anxious, anticipates catastrophic consequences, isolates himself. The family and friends support is essential in these moments, the patient tries cognitive-behavioral psychotherapy, as well as various relaxation techniques, which have positive results for the patient attitude towards the disease. He admits, to complete staging, to follow the recommendations of the oncologist, perform proton emission tomography, which detects the presence of two lesions on the right lung. In January 2018, the surgical intervention is done by straight thoracotomy, atypical upper lobe resection and inferior lobectomy is performed. The histopathological and immunohistochemical results describe the presence of the third primary adenocarcinoma neoplasia. The initial emotional reaction is one of anger, denial, followed by demoralization, easy crying, sadness. The patient is examined by the psychiatrist, thus receiving the diagnosis of a severe depressive episode without psychotic symptoms. He follows an anxiolytic, antidepressant, sedative treatment but continues also the cognitive-behavioral therapy. The patient shows good compliance with psychopharmacological treatment and accepts adjuvant chemotherapy courses, which are well tolerated. Throughout the antineoplastic therapy, there was a close collaboration between the psychiatrist and the oncologist, to avoid drug interactions that could have led to interruption of the treatment. Under the oncology supervision, the patient receives another bad news, in September 2018, the fourth neoplastic localization, the prostatic adenocarcinoma pT2bN0M0, is discovered. In this case, in the presence of the combination of synchronous and methacrone tumors, the patient's psyche is deeply affected, continuing the psychopharmacological treatment. Conclusions: Psychiatric disorders are common among oncological patients, and they may suffer serious impairments in quality of life and treatment compliance, psycho-oncological collaboration being indispensable for the success of antineoplastic treatment.
Style APA, Harvard, Vancouver, ISO itp.

Raporty organizacyjne na temat "Oncology"

1

Kraft, Andrew S. Oncology Center. Office of Scientific and Technical Information (OSTI), wrzesień 2009. http://dx.doi.org/10.2172/964284.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
2

Goldsmith, Brian. Oncology Outreach Evaluation. Fort Belvoir, VA: Defense Technical Information Center, październik 2001. http://dx.doi.org/10.21236/ada396392.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
3

Rose, Gaylord S., i John C. Elkas. Gynecological Oncology Outreach Evaluation. Fort Belvoir, VA: Defense Technical Information Center, grudzień 2002. http://dx.doi.org/10.21236/ada428502.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
4

Mayo id Fuller Ellen D. Yorke Jatinder R. Palta Peter, Charles, Jean Moran, Walter Bosch, Ying Xiao, Todd McNutt, Richard Popple, Jeff Michalski i in. Standardizing Nomenclatures in Radiation Oncology. AAPM, styczeń 2018. http://dx.doi.org/10.37206/171.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
5

Kutcher, Gerald J., Lawrence Coia, Michael Gillin, William F. Hanson, Steven Leibel, Robert J. Morton, Jatinder R. Palta i in. Comprehensive QA for Radiation Oncology. AAPM, 1994. http://dx.doi.org/10.37206/45.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
6

Costa, Jose. Program for Critical Technologies in Breast Oncology. Fort Belvoir, VA: Defense Technical Information Center, lipiec 1996. http://dx.doi.org/10.21236/ada315910.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
7

Asp, Lloyd, Morris Bank, Theodore Fields, William Hendee, Douglas Jones, Colin Orton, Vincent Sampiere i in. The Role of a Physicist in Radiation Oncology. AAPM, 1993. http://dx.doi.org/10.37206/37.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
8

Volkova, Larisa, Oksana Koryakina, Andrey Lazarev, Olga Ovsova, Tatyana Tomenko i Artem Zaichikov. E-cours "Topical lssues in Pediatric Neuro Oncology". SIB-Expertise, grudzień 2022. http://dx.doi.org/10.12731/er0660.15122022.

Pełny tekst źródła
Streszczenie:
Содержание курса раскрывает спектр современных знаний по проблемам нейроонкологической патологии у детей. Рассматриваются такие вопросы как: эпидемиологическая характеристика и принципы классификации опухолей неврной системыу детей, особенности клинических проявлений в зависимости от локализации опухолевого процесса и возраста ребенка, опухолевые факоматозы, структурные формы эпилепсии при объемных образованиях головного мозга, вопросы нейротоксических осложнений химиотерапии у детей. Порядки и стандарты оказания медицинской помощи , наблюдение, пациентов детского возраста с нейроонкологической патологией на амбулаторном этапе после нейрохирургического лечения, важные аспекты паллиативной помощи детям с нейроонкологической патологией.
Style APA, Harvard, Vancouver, ISO itp.
9

Persily, Andrew, W. Stuart Dols, Steven J. Nabinger i David A. VanBronkhorst. Air quality investigation in the NIH Radiation Oncology branch. Gaithersburg, MD: National Institute of Standards and Technology, 1989. http://dx.doi.org/10.6028/nist.ir.89-4145.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
10

Marbach, J. R., M. R. Sontag, J. Van Dyk i A. B. Wolbarst. Management of Radiation Oncology Patients with Implanted Cardiac Pacemakers. AAPM, 1994. http://dx.doi.org/10.37206/44.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
Możesz być także zainteresowany rozszerzonymi bibliografiami na temat „Oncology” dla poszczególnych typów źródeł:
Artykuły w czasopismach Rozprawy doktorskie Książki
Oferujemy zniżki na wszystkie plany premium dla autorów, których prace zostały uwzględnione w tematycznych zestawieniach literatury. Skontaktuj się z nami, aby uzyskać unikalny kod promocyjny!

Do bibliografii